CHEK2 and diffuse large B-cell lymphoma: Our results also showed that HBX conferred resistance to chemotherapeutics that induced S-phase arrest by specifically blocking the activation of checkpoint kinase 2 (CHK2) signaling in vitro and in vivo, which explained the poor outcome caused by HBV infection in DLBCL patients.